NASDAQ:NKTR
Nektar Therapeutics
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
www.nektar.comipo date
May 03, 1994
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasi...Show More
Earnings
Earnings Release in 10 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus